Lv43
480 积分 2024-04-25 加入
Abemaciclib: The First FDA-Approved CDK4/6 Inhibitor for the Adjuvant Treatment of HR+ HER2− Early Breast Cancer
5天前
已完结
Breast pain in lactating women--mastitis or something else?
9天前
已关闭
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
Dalpiciclib versus placebo in combination with letrozole or anastrozole as first-line treatment for women with HR+/HER2- advanced breast cancer: prespecified final analysis of progression-free survival of the phase 3 DAWNA-2 trial
1个月前
已关闭
Ovarian escape in premenopausal breast cancer: Challenges and strategies for optimizing hormone suppression
2个月前
已完结
Chronic Hemolytic Anemia with Paroxysmal Nocturnal Hemoglobinuria
2个月前
已完结
Endocrine therapy or chemotherapy as first-line therapy in hormone receptor–positive HER2-negative metastatic breast cancer patients
2个月前
已完结
Papillomatose respiratoire récurrente
2个月前
已关闭
[Guidelines for diagnosis and treatment of advanced breast cancer in China (2024 edition)]
2个月前
已完结
皖公网安备34019202002308
